These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7508273)

  • 1. Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment.
    Takada K; Katayama N; Kiriyama A; Usuda H
    Biopharm Drug Dispos; 1993 Nov; 14(8):659-71. PubMed ID: 7508273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A.
    Takada K; Usuda H; Oh-Hashi M
    Biopharm Drug Dispos; 1992 Jul; 13(5):345-55. PubMed ID: 1379839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of baboon lymphocytes to cyclosporin A and FK 506: relative resistance of alloactivated cells to CyA.
    Stark JH; Smit JA; Gridelli B
    Transpl Int; 1994 Aug; 7(5):372-8. PubMed ID: 7527639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes.
    Ahmed SS; Strobel HW; Napoli KL; Grevel J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1047-54. PubMed ID: 7685382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats.
    Takada K; Usuda H; Oh-Hashi M; Yoshikawa H; Muranishi S; Tanaka H
    J Pharmacobiodyn; 1991 Jan; 14(1):34-42. PubMed ID: 1713626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes.
    Marks WH; Ma Y; Yirdaw G; Florence L
    Transplantation; 1997 Jan; 63(2):293-8. PubMed ID: 9020333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs.
    Takaori K; Nio Y; Inoue K; Tun T; Fukumoto M; Hashida T; Yasuhara M; Hori R; Tobe T
    Biotherapy; 1992; 4(2):129-37. PubMed ID: 1377926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid withdrawal 3 months after liver transplantation--does FK 506 confer any advantage over cyclosporin?
    Dmitrewski J; Ayres S; Gunson BK; Buist LJ; Buckels JA; McMaster P; Mayer AD
    Transpl Int; 1994; 7 Suppl 1():S85-7. PubMed ID: 11271342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.
    Pham SM; Kormos RL; Hattler BG; Kawai A; Tsamandas AC; Demetris AJ; Murali S; Fricker FJ; Chang HC; Jain AB; Starzl TE; Hardesty RL; Griffith BP
    J Thorac Cardiovasc Surg; 1996 Apr; 111(4):764-72. PubMed ID: 8614136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PHA induced mononuclear cell proliferation by FK506 in combination with cyclosporine, methylprednisolone, 6-mercaptopurine and mycophenolic acid.
    Hibbins M; Inutsuka S; Chapman JR
    Transpl Immunol; 1993; 1(1):66-71. PubMed ID: 7521736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cremophor EL releases cyclosporin A adsorbed on blood cells and blood vessels, and increases apparent plasma concentration of cyclosporin A.
    Jin M; Shimada T; Yokogawa K; Nomura M; Mizuhara Y; Furukawa H; Ishizaki J; Miyamoto K
    Int J Pharm; 2005 Apr; 293(1-2):137-44. PubMed ID: 15778051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats.
    Mysliwiec J; Azzadin A; Chabielska E; Takada A; Mysliwiec M; Buczko W
    Thromb Res; 1996 Jul; 83(2):175-81. PubMed ID: 8837316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506.
    Mor E; Patel T; Glabman S; Sheiner P; Emre S; Guy S; Schwartz M; Miller C
    Transpl Int; 1994; 7 Suppl 1():S77-80. PubMed ID: 11271340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.
    Woo J; Propper DJ; Macleod AM; Thomson AW
    Clin Exp Immunol; 1990 Dec; 82(3):462-8. PubMed ID: 1702375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter--why cyclosporine is monitored by C(2) level and tacrolimus by trough level--.
    Takeuchi H; Matsuno N; Senuma K; Hirano T; Yokoyama T; Taira S; Kihara Y; Kuzuoka K; Konno O; Jojima Y; Mejit A; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Ashizawa T; Nagao T; Toraishi T; Okuyama K; Oka K; Unezaki S
    Biol Pharm Bull; 2008 Jan; 31(1):90-4. PubMed ID: 18175948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar?
    Morozumi K; Sugito K; Oda A; Takeuchi O; Fukuda M; Usami T; Oikawa T; Fujinami T; Koyama K; Takeda A; Yoshida A; Haba T; Tominaga Y; Uchida K; Yokoyama I; Takagi H
    Transplant Proc; 1996 Apr; 28(2):1076-8. PubMed ID: 8623232
    [No Abstract]   [Full Text] [Related]  

  • 19. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.
    Radermacher J; Meiners M; Bramlage C; Kliem V; Behrend M; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R
    Transpl Int; 1998; 11(1):3-10. PubMed ID: 9503547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
    Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.